IceCure launches ChoICE post-marketing study of ProSense cryoablation for low-risk breast cancer in US
ICCM•ChoICE post-marketing study begins at first U.S. site
IceCure Medical launched its post-marketing ChoICE study for ProSense cryoablation in low-risk breast cancer at its first U.S. clinical site.
West Cancer Center & Research Institute in Germantown, Tennessee will begin enrolling patients, with Dr. Richard Gilmore leading the site.
Study to collect real-world evidence across U.S. sites
The study will collect real-world evidence to support broader clinical adoption and expand access following FDA marketing authorization in October 2025.
Results have not been presented; data will be generated as enrollment progresses across up to 400 patients at 30 U.S. sites.
